NDA 018602 · Bausch
Cardizem
Diltiazem Hydrochloride · Oral
NovelLast checked: Nov 19, 2026Latest source record: Apr 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1982
Nov 5, 1982
Approved uses
4
Original approval plus efficacy supplements
Registered trials
127
21 Phase 3, 6 recruiting
FAERS reports
23,272
17,790 serious, 4,039 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 30, 2025.
INDICATIONS AND USAGE CARDIZEM is indicated for the management of chronic stable angina and angina due to coronary artery spasm.
Mechanism: Mechanisms of Action Although precise mechanisms of its antianginal actions are still being delineated, CARDIZEM is believed to act in the following ways: Angina Due to Coronary Artery Spasm: CARDIZEM has been shown to be a potent dilator of coronary arteries both epicardial and subendocardial. Spontaneous and ergonovine-induced coronary artery spasms are inhibited by CARDIZEM. Exertional Angina: CARDIZEM has been shown to produce increases in exercise tolerance, probably due to its ability to reduce myocardial oxygen demand. This is accomplished via reductions in heart rate and systemic...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 1, 1993 Supplement 23 · Efficacy
- Dec 8, 1986 Supplement 20 · Efficacy
- Jul 28, 1986 Supplement 11 · Efficacy
- Nov 5, 1982 Original approval · Type 1 - New Molecular Entity
4 products under this application
- CARDIZEM · DILTIAZEM HYDROCHLORIDE 90MG · TABLET, ORAL · Prescription · TE AB
- CARDIZEM · DILTIAZEM HYDROCHLORIDE 30MG · TABLET, ORAL · Prescription · TE AB
- CARDIZEM · DILTIAZEM HYDROCHLORIDE 120MG · TABLET, ORAL · Prescription · TE AB
- CARDIZEM · DILTIAZEM HYDROCHLORIDE 60MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Diltiazem" as an intervention, any sponsor and status, largest first.
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- Coronavirus (COVID-19) ACEi/ARB InvestigationPivotal-lookingSuspended
National University of Ireland, Galway, IrelandAcademic, hospital or other
NCT04330300 · 2,414 participants (planned) · Start Apr 30, 2020 · Primary completion Jul 31, 2021
Drug: Thiazide or Thiazide-like diuretics; Calcium Channel Blockers and 2 more · For: Hypertension; COVID-19
Sites: Galway, Ireland
- Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation TrialPivotal-lookingCompleted
Mayo ClinicAcademic, hospital or other
NCT00911508 · 2,204 participants · Start Nov 13, 2009 · Primary completion Dec 31, 2017
Drug: Rate or Rhythm Control Therapy · For: Atrial Fibrillation; Arrhythmia
Sites: Little Rock, Arkansas; Los Angeles, California; Sacramento, California · 118 sites in all
- Antihypertensive Treatment of Acute Cerebral Hemorrhage-IIPivotal-lookingTerminated
University of MinnesotaAcademic, hospital or other
NCT01176565 · 1,000 participants · Start May 15, 2011 · Primary completion Dec 21, 2015
Drug: Intravenous nicardipine hydrochloride · For: Intracerebral Hemorrhage
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 171 sites in all
- Flecainide Safety in Patients With Coronary Artery Disease and Atrial FibrillationPivotal-lookingRecruiting
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
NCT07405671 · 988 participants (planned) · Start Sep 2026 · Primary completion Dec 2029
Drug: flecainide; Sotalol or Amiodarone · For: Atrial Fibrillation (AF); Coronary Artery Disease
Sites: Aalst, Belgium; Bonheiden, Belgium; Bruges, Belgium · 14 sites in all
- HALT Progression of Polycystic Kidney Disease Study APivotal-lookingCompleted
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00283686 · 558 participants · Start Jan 2006 · Primary completion Jun 2014
Drug: Lisinopril; Telmisartan and 1 more · For: Kidney, Polycystic
Sites: Aurora, Colorado; Atlanta, Georgia; Kansas City, Kansas · 7 sites in all
Lewai Sharki Abdulaziz, MSc PhDAcademic, hospital or other
NCT04017845 · 537 participants · Start Apr 1, 2015 · Primary completion May 30, 2017
Drug: Tribenoside 400 mg + lidocaine 40 mg suppositories; Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment · For: Colorectal Neoplasms; Colorectal Cancer; Adenomatous Polyp of Colon
Sites: Baghdad, Iraq
- Diltiazem Hydrochloride Cream for Anal FissurePivotal-lookingCompleted
S.L.A. Pharma AGIndustry
NCT01217515 · 465 participants · Start Oct 2010 · Primary completion Mar 2012
Drug: Diltiazem hydrochloride 4% cream; Diltiazem hydrochloride 2% cream · For: Chronic Anal Fissure
Sites: Sevileva, Bulgaria; Sofia, Bulgaria; Veliko Tarnovo, Bulgaria · 27 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea2,392
- fatigue2,001
- pain1,858
- nausea1,717
- dizziness1,638
- diarrhoea1,549
- fall1,526
- headache1,486
- drug ineffective1,458
- arthralgia1,291
- atrial fibrillation1,262
- asthenia1,237
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 837 |
| 2005 | 894 |
| 2006 | 759 |
| 2007 | 579 |
| 2008 | 568 |
| 2009 | 649 |
| 2010 | 920 |
| 2011 | 966 |
| 2012 | 981 |
| 2013 | 865 |
| 2014 | 988 |
| 2015 | 1,179 |
| 2016 | 1,196 |
| 2017 | 1,073 |
| 2018 | 960 |
| 2019 | 894 |
| 2020 | 956 |
| 2021 | 1,146 |
| 2022 | 1,687 |
| 2023 | 1,288 |
| 2024 | 1,524 |
| 2025 | 1,457 |
| 2026 | 905 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cardizem (Diltiazem HCl)
2024 spending
$144K
Beneficiaries
34
96 claims
Per beneficiary
$4,241
$8.51 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $447,835 |
| 2021 | $363,921 |
| 2022 | $305,394 |
| 2023 | $224,141 |
| 2024 | $144,190 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Anti-hypertensive therapy for preeclampsia: a network meta-analysis and systematic review.
Wang T, Jiang R, Yao Y, et al. · Hypertens Pregnancy 2024 · Systematic Review, Network Meta-Analysis
- The diltiazem-digoxin interaction.
Rameis H, Magometschnigg D, Ganzinger U · Clin Pharmacol Ther 1984 · Clinical Trial, Randomized Controlled Trial
- Calcium channel blockers for antipsychotic-induced tardive dyskinesia.
Essali A, Soares-Weiser K, Bergman H, et al. · Cochrane Database Syst Rev 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Randomized clinical trial with topical diltiazem for post-hemorrhoidectomy wound healing.
Rodríguez-Wong U, Rodríguez-Medina U, Medina-Murillo GR · Rev Gastroenterol Mex (Engl Ed) 2019 · Randomized Controlled Trial
- Diltiazem for nocturnal leg cramps.
Voon WC, Sheu SH · Age Ageing 2001 · Clinical Trial, Letter
- Topical diltiazem for pain after closed hemorrhoidectomy.
Rodríguez-Wong U, Ocharán-Hernández ME, Toscano-Garibay J · Rev Gastroenterol Mex 2016 · Randomized Controlled Trial
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.